Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox‐ independent mechanism

A range of antineoplastic properties is attributed to aspirin, thought to be due to inhibition of cyclooxygenase (Cox) enzymes in tumor cells. One important outcome is that by reducing angiogenic factor secretion by cancer cells, aspirin also inhibits angiogenesis, thereby restricting tumor growth. However, aspirin may also have direct effects on endothelial cells to regulate angiogenesis. Our aim was to quantitate these effects and determine whether they occurred through inhibiting Cox enzymes. The effects of aspirin, salicylate (the natural deacetylated form of aspirin), and the selective Cox inhibitors SC560 and Celecoxib on endothelial cell proliferation, viability, and angiogenesis were compared. Therapeutic aspirin concentrations (0.5 mM) had no detectable effect on endothelial cell viability or proliferation but caused a striking reduction in tubule formation in a three‐dimensional collagen angiogenesis assay. This was also seen with equimolar concentrations of salicylate, while selective Cox inhibitors did not inhibit angiogenesis in this assay either alone or in combination. Furthermore, high doses of aspirin or salicylate (5 mM), well above therapeutic plasma concentrations, lead to endothelial cell apoptosis. We conclude that aspirin, at therapeutic concentrations, directly inhibits angiogenesis via a Cox‐independent mechanism, which may significantly contribute to its neoplastic protective effects. —Borthwick, G. M., Johnson, A. S., Partington, M., Burn, J., Wilson, R., Arthur, H. M. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox‐independent mechanism. FASEB J. 20, 2009–2016 (2006)

[1]  J. Kos,et al.  Intracellular proteolytic activity of cathepsin B is associated with capillary‐like tube formation by endothelial cells in vitro , 2006, Journal of cellular biochemistry.

[2]  F. Kabbinavar,et al.  Bevacizumab Combined with Standard Fluoropyrimidine-Based Chemotherapy Regimens to Treat Colorectal Cancer , 2005, Oncology.

[3]  M. Abdelrahim,et al.  Cyclooxygenase-2 Inhibitors Decrease Vascular Endothelial Growth Factor Expression in Colon Cancer Cells by Enhanced Degradation of Sp1 and Sp4 Proteins , 2005, Molecular Pharmacology.

[4]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[5]  R. Botting,et al.  COX-3 and the mechanism of action of paracetamol/acetaminophen. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[6]  J. Morrow,et al.  Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. , 2004, Gastroenterology.

[7]  L. Debusk,et al.  Dual functional roles of Tie-2/angiopoietin in TNF-α-mediated angiogenesis , 2004 .

[8]  M. Byrne,et al.  The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas , 2004, European journal of gastroenterology & hepatology.

[9]  R. DuBois,et al.  Cyclooxygenase‐2 and Gastrointestinal Cancer , 2004, Cancer journal.

[10]  R. DuBois,et al.  COX-2 inhibition and colorectal cancer. , 2004, Seminars in oncology.

[11]  S. Gately,et al.  Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. , 2004, Seminars in oncology.

[12]  T. Hla,et al.  Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. DuBois,et al.  Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Vincent,et al.  Activated Ras induces a proangiogenic phenotype in primary endothelial cells , 2004, Oncogene.

[15]  L. Debusk,et al.  Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. , 2004, American journal of physiology. Heart and circulatory physiology.

[16]  H. Juneja,et al.  Aspirin and salicylate inhibit colon cancer medium‐ and VEGF‐induced endothelial tube formation: correlation with suppression of cyclooxygenase‐2 expression , 2003, Journal of thrombosis and haemostasis : JTH.

[17]  M. Majima,et al.  COX-2/VEGF-Dependent Facilitation of Tumor-Associated Angiogenesis and Tumor Growth in vivo , 2003, Laboratory Investigation.

[18]  J. Little,et al.  Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. , 2003, Gastroenterology.

[19]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[20]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[21]  Yukihiko Sugimoto,et al.  Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003, The Journal of experimental medicine.

[22]  Yukihiko Sugimoto,et al.  Host Prostaglandin E 2-EP 3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003 .

[23]  P. Guillou,et al.  Interstitial cell cyclooxygenase‐2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas , 2002, Journal of Pathology.

[24]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[25]  J. Masferrer,et al.  Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. , 2002, Cancer research.

[26]  F. Cianchi,et al.  Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. , 2001, Gastroenterology.

[27]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[28]  Gerd Geisslinger,et al.  Cyclooxygenase‐independent actions of cyclooxygenase inhibitors , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  S. Maxwell,et al.  Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. , 2001, Journal of cell science.

[30]  Á. Lanas.  Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of reducing the risk of complications , 2001, European journal of gastroenterology & hepatology.

[31]  L. Stark,et al.  Aspirin‐induced activation of the NF‐κB signaling pathway: a novel mechanism for aspirin‐mediated apoptosis in colon cancer cells , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  L. Stark,et al.  Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  M. Tachibana,et al.  Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[35]  F. Peale,et al.  Gene expression profiling in an in vitro model of angiogenesis. , 2000, The American journal of pathology.

[36]  S. Dey,et al.  Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.

[37]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[38]  E. Levin,et al.  Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing , 1999, Nature Medicine.

[39]  M. Gerritsen,et al.  Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. , 1999, The American journal of pathology.

[40]  R. DuBois,et al.  The role of COX-2 in intestinal cancer. , 1999, Annals of the New York Academy of Sciences.

[41]  G. Weissmann,et al.  Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Koboldt,et al.  Pharmacological analysis of cyclooxygenase-1 in inflammation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[44]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[45]  V. Dixit,et al.  Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[46]  K. Seibert,et al.  Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. , 1997, The Journal of pharmacology and experimental therapeutics.

[47]  J. Vilček,et al.  Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Wallace.  Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. , 1997, Gastroenterology.

[49]  S. Baatout.  Endothelial differentiation using Matrigel (review). , 1997, Anticancer research.

[50]  E. A. O'neill,et al.  The Effect of Sodium Salicylate and Aspirin on NF-kappaB , 1995, Science.

[51]  E. A. O'neill,et al.  The effect of sodium salicylate and aspirin on NF-kappa B. , 1995, Science.

[52]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[53]  D. Breuer,et al.  Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. , 1994, The Journal of pharmacology and experimental therapeutics.

[54]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[55]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[56]  David A Jones,et al.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. , 1993, The Journal of biological chemistry.

[57]  R. Swerlick,et al.  HMEC-1: establishment of an immortalized human microvascular endothelial cell line. , 1992, The Journal of investigative dermatology.

[58]  K. Seibert,et al.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. , 1990, The Journal of biological chemistry.

[59]  K. Seibert,et al.  Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. , 1990, The Journal of clinical investigation.

[60]  S. Shak,et al.  Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. , 1984, The Journal of clinical investigation.

[61]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[62]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.